| Literature DB >> 5002115 |
C J Burns-Cox, K P Chandrasekhar, H Ikram, T H Peirce, J Pilcher, C D Quinlan, J R Rees.
Abstract
This paper reports a double-blind trial of a new antianginal drug, perhexiline. Fifty-five patients suffering from angina pectoris were studied for periods of 12 or 24 weeks in a cross-over comparison against a placebo in four centres in the United Kingdom and Ireland. Perhexiline was effective in most patients as judged by reducing the number of anginal attacks in 84% and the consumption of glyceryl trinitrate tablets in 64%. The major side effect, dizziness, noted in one-third of the patients, may be dose/body-weight related. Perhexiline is a valuable new agent for the treatment of patients with angina, especially those who do not respond to other antianginal agents.Entities:
Mesh：
Substances：
Year: 1971 PMID： 5002115 PMCID： PMC1799955 DOI： 10.1136/bmj.4.5787.586
Source DB: PubMed Journal: Br Med J ISSN： 0007-1447